期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 181, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.addr.2021.114081
关键词
Therapeutic nucleic acids; Nucleic acid nanotechnology; Dna origami; Non-viral vector; Vaccine
资金
- National Institutes of Health [R21-EB026008, R21-EB026008-S1, R01-MH112694]
- National Institute of General Medical Sciences of the National Institutes of Health [R01GM120487, R35GM139587]
- Office of Naval Research [N00014-20-1-2084, N00014-21-1-4013]
- Army Research Office [W911NF-13-D-0001]
- National Science Foundation [CCF-1564025, CBET-1729397]
- National Science Foundation
- National Cancer Institute
The field of therapeutic nucleic acid nanotechnology has made significant advances, with the emergence of nucleic acid nanoparticles (NANPs) offering unique properties for applications in cancer diagnosis and therapy, regulation of blood coagulation disorders, and the development of novel vaccines, immunotherapies, and gene therapies.
With numerous recent advances, the field of therapeutic nucleic acid nanotechnology is now poised for clinical translation supported by several examples of FDA-approved nucleic acid nanoformulations including two recent mRNA-based COVID-19 vaccines. Within this rapidly growing field, a new subclass of nucleic acid therapeutics called nucleic acid nanoparticles (NANPs) has emerged in recent years, which offers several unique properties distinguishing it from traditional therapeutic nucleic acids. Key unique aspects of NANPs include their well-defined 3D structure, their tunable multivalent architectures, and their ability to incorporate conditional activations of therapeutic targeting and release functions that enable diagnosis and therapy of cancer, regulation of blood coagulation disorders, as well as the develop-ment of novel vaccines, immunotherapies, and gene therapies. However, non-consolidated research developments of this highly interdisciplinary field create crucial barriers that must be overcome in order to impact a broader range of clinical indications. Forming a consortium framework for nucleic acid nan-otechnology would prioritize and consolidate translational efforts, offer several unifying solutions to expedite their transition from bench-to-bedside, and potentially decrease the socio-economic burden on patients for a range of conditions. Herein, we review the unique properties of NANPs in the context of therapeutic applications and discuss their associated translational challenges.(c) 2021 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据